Abstract | BACKGROUND: METHODS: We evaluated LSD1 expression in CRC tissues from patients who received 5-FU treatment. The synergistic antitumor effect of 5-FU with ZY0511 against human CRC cells was detected both in vitro and in vivo. The underlying mechanism was explored based on mRNA sequencing ( mRNA-seq) technology. RESULTS: Overexpression of LSD1 was observed in human CRC tissues, and correlated with CRC development and 5-FU resistance. ZY0511, a novel LSD1 inhibitor, effectively inhibited CRC cells proliferation, both in vitro and in vivo. Notably, the combination of ZY0511 and 5-FU synergistically reduced CRC cells viability and migration in vitro. It also suppressed Wnt/β- catenin signaling and DNA synthesis pathways, which finally induced apoptosis of CRC cells. In addition, the combination of ZY0511 with 5-FU significantly reduced CRC xenograft tumor growth, along with lung and liver metastases in vivo. CONCLUSIONS: Our findings identify LSD1 as a potential marker for 5-FU resistance in CRC. ZY0511 is a promising candidate for CRC therapy as it potentiates 5-FU anticancer effects, thereby providing a new combinatorial strategy for treating CRC.
|
Authors | Wen Peng, Huaqing Zhang, Shisheng Tan, Yan Li, Yang Zhou, Liang Wang, Chunqi Liu, Qiu Li, Xiaobo Cen, Shengyong Yang, Yinglan Zhao |
Journal | Therapeutic advances in medical oncology
(Ther Adv Med Oncol)
Vol. 12
Pg. 1758835920937428
( 2020)
ISSN: 1758-8340 [Print] England |
PMID | 32754230
(Publication Type: Journal Article)
|
Copyright | © The Author(s), 2020. |